Research Article

Loureirin B Alleviates Myocardial Ischemia/Reperfusion Injury via Inhibiting PAI-1/TGF-β1/Smad Signaling Pathway

Fei Kong1,2 and Meng Zhao13

1Department of Endocrinology, The Fourth Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, China
2Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China
3The First Department of Surgery, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China

Correspondence should be addressed to Meng Zhao; zhaomeng@hljucm.net

Received 22 October 2021; Revised 28 March 2022; Accepted 4 April 2022; Published 30 April 2022

Academic Editor: Jian-You Guo

Copyright © 2022 Fei Kong and Meng Zhao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Myocardial infarction (MI) is a leading cause of death in patients with cardiovascular diseases [1]. Timely reperfusion by thrombolytic treatment or surgical intervention is considered as the most effective method to reduce infarct size and recover cardiac function after MI [2]. However, the reperfusion after ischemia may aggravate cell death and cause irreversible damages to the myocardial structure [3]. Unfortunately, effective therapy for preventing myocardial ischemia/reperfusion (MI/R) injury has not been developed so far [4]. Therefore, it is still of great importance to understand the molecular mechanism and to seek for effective strategies to prevent MI/R injury. Increasing evidence has uncovered that inflammation is a predominant event involved in the pathogenesis of MI/R injury, which is advanced by various proinflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β [5, 6]. TNF-α has been reported to lead to MI/R-induced adverse left ventricular (LV) remodeling and contractile dysfunction [7]. During the process of pathological LV remodeling, cardiac fibroblasts expand and migrate to the injured lesions and transdifferentiate into myofibroblasts. The myofibroblasts contribute greatly to excessive extracellular matrix (ECM) deposition and fibrotic scar formation, which may eventually result in myocardial fibrosis and heart failure [8, 9].

Sanguis draxonis (also known as “Dragon’s Blood”) is a traditional Chinese herbal medicine with a variety of pharmacological activities (anti-inflammation, analgesia, antibiosis, antithrombosis, etc.), which has been clinically
applied in the treatment of trauma, gynecopathy, and blood stasis syndrome [10]. A recent report demonstrated that sanguis draxonis can protect against the apoptosis of myocardial cells induced by MI/R in tree shrews [11]. Loureirin B (LrB) is a kind of flavonoid separated from sanguis draxonis. Sun et al. found that LrB can attenuate the inflammation in an experimental inflammatory bowel disease model of rats [12]. Bai et al. reported that LrB inhibits fibroblast proliferation and extracellular matrix deposition in the scar tissue of rabbits [13]. These findings suggest the anti-inflammatory and antifibrotic functions of LrB. Nonetheless, little is known about the role of LrB in MI/R-induced inflammatory response and fibrosis.

Plasminogen activator inhibitor-1 (PAI-1) is a negative regulator in the fibrinolytic system, which inhibits the activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) [14]. Growing evidence has indicated that PAI-1 participates in the pathogenesis of various fibrosis-related diseases, such as liver fibrosis, lung fibrosis, and kidney fibrosis [15–17]. Moreover, plasma PAI-1 is upregulated in patients with MI [18]. In a mouse model of MI, PAI-1 is highly expressed in the cardiac tissues and is demonstrated to contribute to myocardial fibrosis [19]. These findings implicate that PAI-1 may play a critical role in MI-induced myocardial fibrosis. Interestingly, LrB has been reported to inhibit the activity of PAI-1 and exhibited potential therapeutic effects on thrombotic diseases and fibrotic diseases [20]. However, the effect of LrB in MI/R injury has not been elucidated yet. In the present study, our aim was to investigate the potential function of LrB in MI/R in vivo and in vitro. Moreover, the relationship between LrB and PAI-1 was also investigated.

2. Materials and Methods

2.1. MI/R Model of Mice. All animal studies were approved and performed in accordance with the Ethics Committee of First Affiliated Hospital, Heilongjiang University of Chinese Medicine. Male C57BL/6j mice aged 6 weeks old were adaptively fed for 1 week and divided into sham group, MI/R group, MI/R + 0.5 mg/kg LrB group, and MI/R + 1 mg/kg LrB group. To establish an animal MI/R model, mice were anesthetized by intraperitoneal injection of 50 mg/kg pentobarbital sodium, intubated and mechanically ventilated. After open-chest operation, the left anterior descending coronary artery (LAD) was occluded for 30 min before recovering the blood flow. In the sham group, mice were performed with open-chest operation but did not suffer from MI/R. For drug treatment, mice in the MI/R + 0.5 mg/kg LrB group and the MI/R + 1 mg/kg LrB group received 0.5 mg/kg LrB (Meilunbio, Dalian, China) and 1 mg/kg LrB by intraperitoneal injection per day, respectively [20]. The Sham and MI/R groups were injected with normal saline. Four weeks later, the LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), LV fractional shortening (LVFS), and LV ejection fraction (LVEF) of the mice were detected using a GE Voluson E8 color Doppler ultrasound diagnosis system (General Electric, Boston, MA, USA).

2.2. Determination of Myocardial Infarct Size. Mice were sacrificed by intraperitoneal injection of 200 mg/kg pentobarbital sodium, and the cardiac tissues were collected. After washing with saline, the cardiac tissues were preserved at −20 °C for 3 h and then sliced. The slices were immersed in 2 mL 2% TTC solution (Aladdin, Shanghai, China) and incubated at 37 °C for 30 min. The infarct area (white or pale) and noninfarct area (red) were analyzed using Image-Pro Plus 6.0 software, and the percentage of infarct area was calculated.

2.3. ELISA for Inflammatory Cytokines. Cardiac tissues were mechanically made into 10% homogenate on ice and centrifuged at 430 g for 10 min to obtain the supernatant. Protein concentration was determined by a BCA assay kit (Beyotime, Haimen, China) according to the protocols. Concentrations of TNF-α, IL-1β, and IL-6 in the supernatant were assessed by commercial ELISA kits following the manufacturer’s instructions (USCN Life Science, Wuhan, China).

2.4. Masson’s Trichrome Staining. The cardiac tissues were successively immersed in 70%, 80%, 90%, and 100% ethanol for dehydration, embedded in paraffin, and sectioned into slices of 5 μm. For Masson’s trichrome staining, the slices were incubated with hematoxylin solution (Solarbio, Beijing, China) for 6 min and washed with distilled water. After drying using absorbent paper, the slices were incubated with Ponceau S and acid fuchsins solution (Sinopharm, Beijing, China) for 1 min and then rinsed with 0.2% acetic acid solution. At last, the slices were stained with aniline blue solution and examined under a microscope (OLYMPUS, Tokyo, Japan). The quantitative analysis of the relative staining was performed using Image-Pro Plus 6.0 software.

2.5. Immunofluorescence Staining for PAI-1. The cardiac tissue slices were repaired with antigen retrieval solution for 10 min and rinsed with phosphate buffer solution (PBS) for 3 times. After immersion in goat serum (Solarbio) at room temperature for 15 min, the slices were incubated with primary antibody for PAI-1 (1:100 dilution; Abcam, Cambridge, UK) at 4 °C overnight and rinsed with PBS for 3 times. Then, the slices were incubated with Cy3-labeled goat anti-rabbit immunoglobulin G (IgG) (1:200 dilution; Beyotime) at room temperature for 60 min. At last, the slices were stained with DAPI solution (Beyotime). The developed tissue slices were mounted and examined under a fluorescence microscope.

2.6. Isolation of Cardiac Fibroblasts (CFs). The hearts of mice were harvested in a sterile environment and infused with collagenase II-contained perfusion buffer solution for 3 min. Then, the heart was perfused with digestive buffer solution supplemented with 12.5 μM CaCl$_2$ for 8 min. After cutting into small pieces, the heart tissues were treated with buffer solution supplemented with 12.5 μM CaCl$_2$ and 10% fetal bovine serum (Hyclone, Logan, UT, USA), filtered to
remove undigested tissues, and rested for 20 min to collect the cells. The isolated cells were resuspended in the perfusion buffer solution containing 12.5 μM CaCl2 and 5% fetal bovine serum and rested for 20 min to collect the supernatant. After centrifugation at 500 g for 7 min, the cells were seeded onto culture plates coated with 1% gelatin and incubated in Iscove’s modified Dulbecco’s medium (IMDM; Procell, Wuhan, China) at 37°C.

2.7. Cell Identification. For identification, the cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Beyotime) for 30 min, and rinsed with PBS for 3 times. After treatment with goat serum for 15 min, cells were incubated with primary antibody against fibroblast-specific protein 1 (FSP1) (1:200 dilution; ABclonal, Wuhan, China) or α-smooth muscle actin (α-SMA) (1:200 dilution; Abcam) at 4°C overnight. The cells were rinsed with PBS for 3 times and then incubated with Cy3-labeled goat anti-rabbit IgG (1:200 dilution; Beyotime) at room temperature for 30 min. After treatment with goat serum for 15 min, the cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Beyotime) for 30 min, and rinsed with PBS for 3 times. After treatment with goat serum for 15 min, the cells were incubated in Iscove’s modified Dulbecco’s medium (IMDM; Procell, Wuhan, China) at 37°C.

2.8. Cell Treatment. CFs were divided into control group, angiotensin (Ang) II group, Ang II + LrB group, Ang II + LrB + vector group, and Ang II + LrB + PAI-1 OE group. Cells in the Ang II + LrB + PAI-1 OE group were transfected with lentivirus-mediated PAI-1 overexpression (OE) vector, while cells in the Ang II + LrB + vector group were transfected with empty vector. After 48 h, cells in LrB treatment groups were incubated with 25 μg/mL LrB [21] for 1 h. Then, cells in angiotensin (Ang) II treatment groups were incubated with 0.1 μM Ang II (GL Biochem, Shanghai, China) for 24 h.

2.9. Western Blot Analysis. The relative protein expression in the cardiac tissues or CFs was analyzed by Western blot. Samples were treated with RIPA lysis buffer (Solarbio) and centrifuged at 10,000 g (4°C) for 5 min to obtain the protein samples. After quantification with the BCA assay kit, the protein samples were separated using SDS-PAGE (8%, 10%, and 15% separation gel) and transferred onto PVDF membranes (Millipore, Billerica, MA, USA). The membranes were immersed in 5% nonfat milk to block the nonspecific binding for 1 h and incubated at 4°C overnight with primary antibody against fibronectin (1:2000 dilution; ABclonal), collagen I (1:500 dilution; Affinity, Changzhou, China), collagen III (1:1000 dilution; Affinity), α-SMA (1:500 dilution; ABclonal), PAI-1 (1:1000 dilution; Abcam), uPA (1:500 dilution; Affinity), tPA (1:500 dilution; Affinity), TGF-β1 (1:400 dilution; Affinity), TGF-β1R (1:1000 dilution; Affinity), p-Smad2/3 (1:500 dilution; ABclonal), Smad2/3 (1:1000 dilution; Abclonal), and GAPDH (1:10,000 dilution; Proteintech, Wuhan, China). After rinsing with TBSF buffer, the membranes were incubated with HRP-conjugated goat anti-mouse or goat anti-rabbit IgG (1:3000 dilution; Solarbio) at 37°C for 1 h. For visualization of the protein bands, PVDF membranes were treated with ECL reagent (Solarbio) and exposed in the darkroom. The optical density of the protein bands was analyzed using Gel-Pro Analyzer software.

2.10. Real-Time PCR. The relative mRNA expression of PAI-1, uPA, and tPA was analyzed by real-time PCR. Total RNA was extracted and quantified (UV spectrophotometer). RNA samples were reverse-transcribed into cDNA templates on a PCR system (BIONEER, Daejeon, Korea). Quantitative real-time PCR was conducted using the template, primers, Taq HS Perfect Mix (TaKaRa, Tokyo, Japan), and SYBR Green (BioTeke, Beijing, China) on the PCR system. The sequences of primers were shown as follows: PAI-1F, 5′-ATGCCCATCTTTGTCCAGC-3′; PAI-1R, 5′-TCTGAGAAGTCCACCTGTITT-3′; uPA F, 5′-TAGACCAACAGGCTTCC-3′; uPA R, 5′-GAGACTCCACCACATTTA-3′; tPA F, 5′-AGTGCCCCTGATGGATTG-3′; tPA R, 5′-GTCTCTGGTGTTGTTCT-3′.

2.11. Statistical Analysis. All data were shown as mean ± SD. Statistical difference was analyzed by one-way analysis of variance using GraphPad Prism 8.0 software, followed by Turkey’s test for multiple comparison. p < 0.05 was considered statistically significant.

3. Results

3.1. LrB Improved Cardiac Function and Reduced Infarct Size in MI/R Mice. Four weeks after MI/R, cardiac function of mice was evaluated by echocardiographic examination. It was found that mice in the MI/R group showed significantly higher LVEDD and LVEDS than mice in the sham group (Figures 1(a) and 1(b)). Moreover, MI/R mice exhibited significantly lower LVFS and LVEF than mice in the sham group (Figures 1(c) and 1(d)), indicating that MI/R resulted in a decline in LV function in mice. Treatment with 0.5 mg/kg or 1 mg/kg LrB decreased LVEDD and LVEDS in MI/R mice. However, only 1 mg/kg LrB effectively increased LVFS and LVEF in MI/R mice, demonstrating that LrB might improve the cardiac function of MI/R mice in a dose-dependent manner. Additionally, the ratio of heart weight (HW) to body weight (BW) in MI/R mice was decreased by treatment with 1 mg/kg LrB (Figure 1(e)). TTC staining was then performed to access the infarct size. As shown in Figure 1(f), heart cross sections of MI/R mice showed large white infarct area, while the sham group showed normal red color. Treatment with 0.5 mg/kg or 1 mg/kg LrB reduced infarct size in MI/R mice (Figures 1(f) and 1(g)), demonstrating the beneficial effect of LrB on alleviating MI/R injury.

3.2. LrB Attenuated MI/R-Induced Inflammation in Mice. The levels of IL-6, TNF-α, and IL-1β in the cardiac tissues were determined to evaluate the effect of LrB on MI/R-induced inflammation. We found that mice in the MI/R group showed dramatically enhanced levels of IL-6, TNF-α, and IL-1β compared with the sham group (Figures 2(a)–2(c)), indicating that MI/R caused severe inflammation in
Figure 1: Loureirin B (LrB) improved cardiac function and reduced infarct size in mice with myocardial ischemia/reperfusion (MI/R). Mice were subjected to MI/R and treated with 0.5 mg/kg LrB or 1 mg/kg LrB per day for 4 weeks. Four weeks later, cardiac function of the mice was measured, and the cardiac tissues were harvested for further examination. (a) Left ventricular end-diastolic diameter (LVEDD), (b) left ventricular end-systolic diameter (LVESD), (c) left ventricular fractional shortening (LVFS), and (d) left ventricular ejection fraction (LVEF) measured by echocardiographic examination. (e) The ratio of heart weight (HW) to body weight (BW). (f) Representative photographs of heart cross sections after TTC staining. (g) The percentage of myocardial infarct area. Values are expressed as mean ± SD (n = 6). **p < 0.01, +++ p < 0.001 vs. sham group. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. MI/R group.

Figure 2: LrB attenuated MI/R-induced inflammation in mice. The concentrations of (a) interleukin (IL)-6, (b) tumor necrosis factor (TNF)-α, and (c) IL-1β in the cardiac tissues of the mice. Values are expressed as mean ± SD (n = 6). +++ p < 0.001 vs. sham group. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. MI/R group.
the cardiac tissues of mice. Treatment with LrB attenuated the levels of these inflammatory cytokines in a dose-dependent manner, demonstrating the anti-inflammatory effect of LrB on MI/R mice.

3.3. LrB Alleviated MI/R-Induced Myocardial Fibrosis in Mice.

MI/R-induced myocardial fibrosis was assessed by Masson’s trichrome staining. As illustrated in Figure 3(a), the MI/R group exhibited noticeably increased deposition of collagen fiber in the cardiac tissues compared with the sham group. Notably, treating with 0.5 mg/kg or 1 mg/kg LrB effectively reduced the deposition of collagen fiber induced by MI/R. To verify this observation, the expression of fibrosis-associated proteins fibronectin, collagen I, collagen III, and α-SMA in the cardiac tissues was determined by Western blot analysis. As shown in Figures 3(b)–3(f), mice in the MI/R group
expressed significantly higher fibronectin, collagen I, collagen III, and α-SMA, which were abolished after LrB treatment. These results suggested that LrB could alleviate MI/R-induced myocardial fibrosis in mice.

3.4. LrB Suppressed the Expression of PAI-1 and the Activation of TGF-β1/Smad Signaling Pathway in MI/R Mice. The distribution of PAI-1 in cardiac tissues was visualized by immunofluorescence staining. Compared with the sham group, the MI/R group showed more red fluorescence of PAI-1 (Figure 4(a)). By contrast, treating with 1 mg/kg LrB inhibited the expression of PAI-1. In addition, mRNA and protein expression levels of uPA and tPA were dramatically downregulated in the MI/R group, which were reversed by treating with LrB (Figures 4(b) and 4(c)). Furthermore, the protein expression of PAI-1, TGF-β1, TGF-β1R, p-Smad2/3, and Smad2/3 were determined by Western blot analysis (Figures 4(d)–4(i)). The result confirmed that PAI-1 was significantly upregulated in the MI/R group but dramatically downregulated in the MI/R + 1 mg/kg LrB group. Interestingly, MI/R induced the upregulation of TGF-β1, TGF-β1R, and p-Smad2/3 in the cardiac tissues, suggesting that the TGF-β1/Smad signaling pathway was activated in MI/R mice. Treating with LrB significantly downregulated the expression of TGF-β1, TGF-β1R, and p-Smad2/3. The expression of Smad2/3 had no significant difference between these groups.

3.5. LrB Suppressed Ang II-Induced Activation of TGF-β1/Smad Signaling Pathway in CFs via Regulating PAI-1. FSP1 and α-SMA are regarded as specific markers for fibroblasts and myofibroblasts, respectively [22]. Immunofluorescence staining revealed FSP1- and α-SMA-positive areas in these cells (Figure 5(a)). Then, the isolated cells were transfected with PAI-1 OE vector to upregulate the expression of PAI-1, as demonstrated by Western blot analysis (Figure 5(b)). Further, we found that 24-h Ang II treatment significantly enhanced the mRNA and protein levels of PAI-1 in CFs (Figures 5(c) and 5(d)). Treating with LrB suppressed the Ang II-induced upregulation of PAI-1, which was reversed by transfection of PAI-1 OE vector. Moreover, Ang II enhanced the protein expression of TGF-β1, TGF-β1R, and p-Smad2/3 in CFs, which was attenuated by LrB treatment (Figures 5(e)–5(h)). The protein expression of Smad2/3 had no significant difference between these groups (Figure 5(i)). These results indicated that LrB could inhibit the Ang II-induced activation of TGF-β1/Smad signaling pathway. Interestingly, transfecting with PAI-1 OE vector greatly enhanced their expression levels, indicating that the upregulation of PAI-1 impaired the effect of LrB in Ang II-treated CFs. Thus, it was speculated that LrB might suppress the Ang II-induced activation of TGF-β1/Smad signaling pathway in CFs via regulating PAI-1.

3.6. LrB Inhibited Ang II-Induced Expression of Fibronectin, Collagen I, Collagen III, and α-SMA in CFs via Regulating PAI-1. We further analyzed the protein expression of fibronectin, collagen I, collagen III, and α-SMA in Ang II-treated CFs. It was found that these ECM-related proteins were significantly upregulated in the Ang II group compared with the control group (Figures 6(a) and 6(b)). LrB treatment remarkably attenuated the expression of these ECM-related proteins. Interestingly, transfecting with PAI-1 OE vector upregulated their expression in CFs treated with Ang II and LrB.

4. Discussion

MI/R injury can cause arrhythmias, myocardial stunning, microvascular obstruction, and cardiomyocyte damage [2]. Recently, many flavonoids have been demonstrated to show therapeutic effects on MI/R injury. Hu et al. found that luteolin attenuates MI/R injury in mice through regulating calcium transport-associated molecular pathway [23]. Xue et al. reported that vitexin protects against MI/R injury in rats via regulating mitochondrial function [24]. LrB, a kind of flavonoid, has been reported to inhibit oxidative stress in osteoblasts and enhance mitochondrial function after spinal cord injury [25, 26]. However, the potential effect of LrB on MI/R injury has not been reported yet. In the present research, we demonstrated that subjecting to MI/R damaged the LV function, as characterized by decreased LVFS and LVEF. Moreover, MI/R mice suffered massive myocardial infarction, indicating that MI/R induced severe cardiac injury. Interestingly, treating with LrB effectively improved LV function and reduced myocardial infarction size in MI/R mice, suggesting a cardioprotective effect of LrB on MI/R injury.

The mechanism of MI/R damage is complex, and inflammation is the critical pathological feature of cardiac injury [27]. Overactive inflammatory response has been revealed to mediate myocardial cell injury, cardiac dysfunction, and fibrosis [28–32]. To investigate the effect of LrB on MI/R-induced inflammatory response, we determined the concentration of IL-6, TNF-α, and IL-1β in cardiac tissues. Consistent with previous research, MI/R mice shows significantly increased levels of these proinflammatory cytokines, confirming that MI/R exacerbated inflammation in mice. LrB treatment reduced their levels, demonstrating an anti-inflammatory role of LrB in MI/R. Therefore, we speculated that the anti-inflammatory effect of LrB might be related to its cardioprotective effect on MI/R injury.

LV remodeling refers to a series of compensatory alternations in LV architecture and function in response to MI-induced cardiac injury, which usually results in dilatation, hypertrophy, and deterioration of contractile function [9]. MI/R-induced cardiomyocyte death may provoke adverse LV remodeling, myocardial fibrosis, and heart failure [33]. The pathological alternations in LV remodeling are mediated by the interaction of cardiomyocyte hypertrophy, apoptosis, fibroblasts proliferation, and interstitial fibrosis [34]. During LV remodeling, fibroblasts transform into myofibroblasts and migrate to the injured lesions, resulting in excessive deposition of collagen and fibrosis [35]. In the present study, excessive collagen deposition and
Figure 4: LrB suppressed the expression of PAI-1 and the activation of TGF-β1/Smad signaling pathway in MI/R mice. (a) Representative images showing the distribution of PAI-1 in cardiac tissues after immunofluorescence staining. Scale bar = 50 μm. (b, c) Relative mRNA and protein expression of urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) in the cardiac tissues. (d) Western blot analysis for TGF-β1R, TGF-β1, p-Smad2/3, and Smad2/3. Relative protein expression of (e) PAI-1, (f) TGF-β1R, (g) TGF-β1, (h) p-Smad2/3, and (i) Smad2/3 in the cardiac tissues. Values are expressed as mean ± SD (n = 6). ***p < 0.001 vs. sham group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MI/R group.
Figure 5: LrB suppressed angiotensin (Ang) II-induced activation of TGF-β1/Smad signaling pathway in cardiac fibroblasts (CFs) via regulating PAI-1. (a) Representative fluorescent images of fibroblast-specific protein-1 (FSP1) and α-smooth muscle actin (α-SMA) in CFs. Scar bar = 50 μm. (b) Western blot analysis for PAI-1 in CFs transfected with empty vector or PAI-1 overexpression (OE) vector. (c, d) Relative mRNA and protein expression of PAI-1 in CFs. (e) Western blot analysis for TGF-β1R, TGF-β1, p-Smad2/3, and Smad2/3. Relative protein expression of (f) TGF-β1R, (g) TGF-β1, (h) p-Smad2/3, and (i) Smad2/3 in CFs. Values are indicated as mean ± SD (n = 3). +++ p < 0.001 vs. control group. *** p < 0.001 vs. Ang II group. &&& p < 0.001 vs. Ang II + LrB + vector group.
upregulation of fibrosis-related proteins (fibronectin, collagen I, collagen III, and α-SMA) were detected in the cardiac tissues of MI/R mice. However, treatment with LrB attenuated the collagen deposition and the expression of these fibrosis-related proteins, confirming its potential antifibrotic effect on MI/R injury.

PAI-1, an inhibitor of collagen degradation, plays a pivotal role in MI/R development [36]. To further explore how LrB protected against MI/R-induced myocardial fibrosis, we determined the expression of PAI-1 in the cardiac tissues. PAI-1 was abnormally upregulated in an MI mouse model and identified to induce MI-induced myocardial fibrosis [19]. Moreover, LrB was reported to be an inhibitor of PAI-1 [20]. However, it is unknown whether LrB could regulate the expression of PAI-1 in MI/R mice. In this study, the expression of PAI-1 was found to be dramatically upregulated in untreated MI/R mice, which was in line with previous studies. Treatment with LrB reduced the upregulation of PAI-1, demonstrating that LrB could inhibit PAI-1 expression in MI/R. Therefore, inhibition of PAI might contribute to the antifibrotic effect of LrB in MI/R. However, it should be noted that although high expression of PAI-1 was demonstrated to be profibrotic in the cardiac tissue, PAI-1 is cardioprotective in normal physiological levels, and the deficiency of PAI-1 may also lead to myocardial fibrosis [37, 38]. Therefore, the complex mechanism of LrB’s cardioprotective role in MI/R requires further investigation.

TGF-β1/Smads is an essential fibrogenic growth signal in myocardial fibrosis induced by MI [39]. It is well described that TGF-β1 mediates the activation of Smad2/3 and then activated Smad2/3 binds with Smad4 to form a complex to translocate into the nucleus and regulates specific genes [40]. Also, TGF-β1 plays a key profibrotic role in multiple fibrosis-related diseases via regulating fibroblast activation and ECM synthesis [41, 42]. Overexpression of TGF-β1 induced myocardial fibrosis in transgenic mice [43]. Blocking TGF-β1 signaling alleviated myocardial fibrosis and dysfunction in pressure-overloaded rats [44], implicating the specific role of TGF-β1 in promoting myocardial fibrosis. In this study, we found that LrB treatment suppressed the MI/R-induced upregulation of TGF-β1, TGF-β1R, and p-Smad2/3, revealing that LrB might attenuate MI/R-induced myocardial fibrosis via TGF-β1/Smad inactivation, which was correlated with the report of Bai et al. [13].

Activated cardiac fibroblasts play a predominant role in MI/R-induced fibrosis [45]. Ang II has been recognized to enhance myocardial fibrosis through promoting CF activation and production of ECM-related proteins [46]. Here, we found that exposure to Ang II induced the upregulation of PAI-1 and the activation of TGF-β1/Smad signaling pathway in CFs, whereas LrB treatment suppressed it. LrB also suppressed the Ang II-induced upregulation of fibronectin, collagen I, collagen III and α-SMA in CFs, which
could be abolished by overexpressing PAI-1. Therefore, we speculated that LrB might function through regulating PAI-1. In some previous studies, PAI-1 was recognized as a downstream target of TGF-β1, which functioned to inhibit ECM degradation and promote organ fibrosis [47, 48]. Other studies suggested that PAI-1 also modulate the activity of TGF-β1 in turn [49, 50]. Thus, PAI-1 and TGF-β1 may constitute a positive feedback loop and contribute together to the pathogenesis of cardiac fibrosis.

5. Conclusions
Collectively, our in vivo study showed that treatment with LrB improved LV function and reduced myocardial infarction in MI/R mice, demonstrating a cardioprotective effect of LrB on MI/R injury. Moreover, LrB alleviated MI/R-induced myocardial fibrosis, possibly by inhibiting PAI-1 and TGF-β1/Smad. In vitro study further demonstrated that LrB reduced the Ang II-induced activation of TGF-β1/Smad signaling pathway and production of ECM-related proteins in CFs via regulating PAI-1. These findings support this point that LrB might be an effective therapeutic drug for MI/R injury.

Data Availability
The data that support the findings of this study are included in the manuscript.

Ethical Approval
All animal studies were approved by and performed in accordance with the Ethics Committee of the First Affiliated Hospital, Heilongjiang University of Chinese Medicine.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
All persons who meet authorship criteria are listed as authors, and all the authors contributed substantially to the conception or design of the work or the acquisition, analysis, or interpretation of the data for this manuscript.

Acknowledgments
This research was funded by a grant from the National Natural Science Foundation of China (No. 81804054).

Supplementary Materials

Graphical Abstract of the Research. Loureirin B may alleviate MI/R-induced myocardial inflammatory response and fibrosis through inhibiting PAI-1/TGF-β1/Smad signaling pathway. (Supplementary Materials)

References
[1] S. Sahoo and D. W. Losordo, "Exosomes and cardiac repair after myocardial infarction," Circulation Research, vol. 114, no. 2, pp. 333–344, 2014.
[2] D. J. Hauserley and D. M. Yellon, "Myocardial ischemia-reperfusion injury: a neglected therapeutic target," Journal of Clinical Investigation, vol. 123, no. 1, pp. 92–100, 2013.
[3] D. M. Yellon and D. J. Hauserley, "Myocardial reperfusion injury," New England Journal of Medicine, vol. 357, no. 11, pp. 1121-1135, 2007.
[4] H. Amani, R. Habibey, S. J. Hajmiresmail, S. Latiﬁ, H. Pazokit-Toroudi, and O. Akhavan, “Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries,” Journal of Materials Chemistry B, vol. 5, no. 48, pp. 9452–9476, 2017.
[5] C. Moro, M.-G. Jouan, A. Rakotovao et al., "Delayed expression of cytokines after reperfused myocardial infarction: possible trigger for cardiac dysfunction and ventricular remodeling," American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 5, pp. H3014–H3019, 2007.
[6] A. Frank, M. Bonney, S. Bonney, L. Weitzen, M. Koeppen, and T. Eckle, "Myocardial ischemia reperfusion injury," Seminars in Cardiothoracic and Vascular Anesthesia, vol. 16, no. 3, pp. 123–132, 2012.
[7] M. Sun, M. Chen, F. Dawood et al., “Tumor necrosis factor-a mediates cardiac remodeling and ventricular dysfunction after pressure overload state,” Circulation, vol. 115, no. 11, Article ID 1398, 2007.
[8] S. D. Prabhu and N. G. Frangogiannis, “The biological basis for cardiac repair after myocardial infarction,” Circulation Research, vol. 119, no. 1, pp. 91–112, 2016.
[9] M. G. S. J. Sutton and N. Sharpe, “Left ventricular remodeling after myocardial infarction,” Circulation, vol. 101, no. 25, pp. 2981–2988, 2000.
[10] N. Xin, Y.-J. Li, Y. Li et al., “Dragon’s Blood extract has antithrombotic properties, affecting platelet aggregation functions and anticoagulation activities,” Journal of Ethnopharmacology, vol. 135, no. 2, pp. 510–514, 2011.
[11] T.-R. Yang, T. Zhang, N.-H. Mu et al., “Resina draconis inhibits the endoplasmic-reticulum-induced apoptosis of myocardial cells via regulating miR-423-3p/ERK signaling pathway in a tree shrew myocardial ischemia-reperfusion model,” Journal of Biosciences, vol. 44, no. 2, p. 53, 2019.
[12] X. Sun, K. Wen, Z. Xu et al., “Effect of Loureirin B on Crohn’s disease rat model induced by TNBS via IL-6/STAT3/NF-κB signaling pathway,” Chinese Medicine, vol. 15, no. 1, pp. 1–13, 2020.
[13] X. Bai, T. He, J. Liu et al., “Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β1/Smad pathway,” Experimental Dermatology, vol. 24, no. 5, pp. 355–360, 2015.
[14] Y. Izuhara, S. Takahashi, M. Nangaku et al., “Inhibition of plasminogen activator inhibitor-1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 4, pp. 672–677, 2008.
[15] H. Wang, Y. Zhang, and R. O. Heuckeroth, “PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA,” FEBS Letters, vol. 581, no. 16, pp. 3098–3104, 2007.
[16] A. J. Courcy, J. C. Horowitz, K. K. Kim et al., “The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice,” Blood, vol. 118, no. 8, pp. 2313–2321, 2011.
Evidence-Based Complementary and Alternative Medicine

[17] T. Oda, Y. O. Jung, H. S. Kim et al., “PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction,” Kidney International, vol. 60, no. 2, pp. 587–596, 2001.

[18] A. Hamsten, G. Wallldius, A. Szamosi et al., “Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction,” The Lancet, vol. 330, no. 8549, pp. 3–9, 1987.

[19] K. Takeshita, M. Hayashi, S. Iino et al., “Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction,” American Journal Of Pathology, vol. 164, no. 2, pp. 449–456, 2004.

[20] Y. Jiang, G. Zhang, D. Yan, H. Yang, Z. Ye, and T. Ma, “Bioactivity-guided fractionation of the traditional Chinese medicine Resina Draconis reveals Loureirin B as a PAI-1 inhibitor,” Evidence-based Complementary and Alternative Medicine: ECAM, vol. 2017, Article ID 9425963, 8 pages, 2017.

[21] T. He, X. Bai, L. Yang et al., “Loureirin B inhibits hypertrophic scar formation via inhibition of the TGF-β1-ERK1/INK pathway,” Cellular Physiology and Biochemistry, vol. 37, no. 2, pp. 666–676, 2015.

[22] Y. Ji, Y.-N. Dou, Q.-W. Zhao et al., “Paenoniflorin suppresses TGF-β mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway,” Acta Pharmacologica Sinica, vol. 37, no. 6, pp. 794–804, 2016.

[23] Y. Hu, C. Zhang, H. Zhu et al., “Luteolin modulates SERCA2a via Sp1 upregulation to attenuate myocardial ischemia/reperfusion injury in mice,” Scientific Reports, vol. 10, no. 1, pp. 15407–15412, 2020.

[24] W. Xue, X. Wang, H. Tang et al., “Vitexin attenuates myocardial ischemia/reperfusion injury in rats by regulating mitochondrial dysfunction induced by mitochondrial dynamics imbalance,” Biomedicine & Pharmacotherapy, vol. 124, Article ID 109849, 2020.

[25] Y. Liu, C. Wang, G. Wang et al., “Loureirin B suppresses RANKL-induced osteoclastogenesis and ovarietomized osteoporosis via attenuating NFATc1 and ROS activities,” Theranostics, vol. 9, no. 16, pp. 4648–4662, 2019.

[26] Q. Wang, H. Cai, Z. Hu et al., “Loureirin B promotes axon regeneration by inhibiting endoplasmic reticulum stress: induced mitochondrial dysfunction and regulating the akt/GSK-3β pathway after spinal cord injury,” Journal of Neurotrauma, vol. 36, no. 12, pp. 1949–1964, 2019.

[27] N. G. Frangogiannis, “Inflammation in cardiac injury, repair and regeneration,” Current Opinion in Cardiology, vol. 30, no. 3, pp. 240–245, 2015.

[28] J. Vinten-Johansen, “Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury,” Cardiovascular Research, vol. 61, no. 3, pp. 481–497, 2004.

[29] M. Kawaguchi, M. Takahashi, T. Hata et al., “Inflammomosome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury,” Circulation, vol. 123, no. 6, pp. 594–604, 2011.

[30] S. Toldo, C. Marchetti, A. G. Mauro et al., “Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse,” International Journal of Cardiology, vol. 209, pp. 215–220, 2016.

[31] J. Guo, S.-B. Wang, T.-Y. Yuan et al., “Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation,” Atherosclerosis, vol. 231, no. 2, pp. 384–391, 2013.

[32] R. Badalzadeh, B. Baradaran, A. Alilhemmati, B. Yousefi, and A. Abbaspazadeh, “Troexerin preconditioning and ischemic Postconditioning modulate inflammatory response after myocardial ischemia/reperfusion injury in rat model,” Inflammation, vol. 40, no. 1, pp. 136–143, 2017.

[33] Q.-Q. Wu, Y. Xiao, Y. Yuan et al., “Mechanisms contributing to cardiac remodelling,” Clinical Science, vol. 131, no. 18, pp. 2319–2345, 2017.

[34] M. A. Konstam, D. G. Kramer, A. R. Patel, M. S. Maron, and J. E. Udelson, “Left ventricular remodeling in heart failure,” Journal of the American College of Cardiology: Cardiovascular Imaging, vol. 4, no. 1, pp. 98–108, 2011.

[35] D. L. Sonin, T. Wakatsuki, K. V. Routhu et al., “Protease-activated receptor 1 inhibition by SCH 9797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 18, no. 5, pp. 460–475, 2013.

[36] Y.-S. Kim, H. S. Kang, R. Herbert et al., “Kruppel-Like zinc finger protein Glis2 is essential for the maintenance of normal renal functions,” Molecular and Cellular Biology, vol. 28, no. 7, pp. 2358–2367, 2008.

[37] Z. Xu, F. J. Castellino, and V. A. Ploplis, “Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture,” Blood, The Journal of the American Society of Hematology, vol. 115, no. 10, pp. 2038–2047, 2011.

[38] A. K. Ghosh, W. S. Bradham, L. A. Gleaves et al., “Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice,” Circulation, vol. 122, no. 12, pp. 1200–1209, 2010.

[39] L. Gao, L.-Y. Wang, Z.-Q. Liu et al., “TNAP inhibition attenuates cardiac fibrosis induced by myocardial infarction through deactivating TGF-β1/Smads and activating P35 signaling pathways,” Cell Death & Disease, vol. 11, no. 1, p. 44, 2020.

[40] X.-M. Meng, D. J. Nikolic-Paterson, and H. Y. Lan, “TGF-β: the master regulator of fibrosis,” Nature Reviews Nephrology, vol. 12, no. 6, pp. 325–338, 2016.

[41] F. T. Borges, S. A. Melo, B. C. Özdemir et al., “TGF-β1-Containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis,” Journal of the American Society of Nephrology, vol. 24, no. 3, pp. 385–392, 2013.

[42] Y. Wei, T. J. Kim, D. H. Peng et al., “Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis,” Journal of Clinical Investigation, vol. 127, no. 10, pp. 3675–3688, 2017.

[43] U. Seeland, C. Haeuseler, R. Hinrichs et al., “Myocardial fibrosis in transforming growth factor-β1(TGF-β1) transgenic mice is associated with inhibition of interstitial collagenase,” European Journal of Clinical Investigation, vol. 32, no. 5, pp. 295–303, 2002.

[44] R. K. Wu, H. Kai, K. Tokuda et al., “Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats,” Circulation, vol. 106, no. 1, pp. 130–135, 2002.

[45] M. D. Tallquist and J. D. Molkentin, “Redefining the identity of the master regulator of fibrosis,” Nature, vol. 471, no. 7341, pp. 1228–1232, 2009.
[48] B. Guo, K. Inoki, M. Isono et al., “MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-β in rat mesangial cells,” Kidney International, vol. 68, no. 3, pp. 972–984, 2005.

[49] J. Y. Seo, J. Park, M. R. Yu, Y. S. Kim, H. Ha, and H. B. Lee, “Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes,” American Journal of Nephrology, vol. 30, no. 6, pp. 481–490, 2009.

[50] S. Krag, C. C. Danielsen, P. Carmeliet, J. Nyengaard, and L. Wogensen, “Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-β1-induced kidney disease,” Kidney International, vol. 68, no. 6, pp. 2651–2666, 2005.